DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes? DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes?
Top-line data from DECLARE-TIMI 58 hint that CV benefit of the SGLT2 inhibitor dapagliflozin for type 2 diabetes is driven by improvement in heart failure, but 60% of patients were primary prevention.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
More News: Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Health | Heart | Heart Failure | SGLT2 Inhibitors